Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The role of immune checkpoint receptors in the malignant phenotype of cutaneous T cell lymphoma.

Immunologic research - 1 Dec 2022

Shreberk-Hassidim Rony, Geiger-Maor Anat, Eisenberg Galit, Merims Sharon, Hajaj Emma, Cohen Jonathan E, Klein Shiri, Frankenburg Shoshana, Moyal Lilach, Hodak Emilia, Zlotogorski Abraham, Lotem Michal

Abstract excerpt

Immune checkpoint receptors (ICR) modulate the immune response and are critical hubs for immunotherapy. However, data on their role in T lymphoid malignancies, such as cutaneous T cell lymphoma (CTCL), is sparse. We aimed to explore the role of ICR in the malignant features of transformed T lymphocytes and evaluate the effect of ICR-targeting monoclonal antibodies, often used as immunotherapy for solid tumors. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Ligands

Share to Lymphoma, T-Cell, Cutaneous

Share to Phenotype

Share to Programmed Cell Death 1 Receptor

Source

Identifiers

PMID: 35867216
DOI: 10.1007/s12026-022-09308-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The role of immune checkpoint receptors in the malignant phenotype of cutaneous T cell lymphoma.PMID 35867216Read ↗

Non-coding RNAs in the spotlight of the pathogenesis, diagnosis, and therapy of cutaneous T cell lymphomaSemantic proximity Read ↗

Genetic and epigenetic insights into cutaneous T-cell lymphomaSemantic proximity Read ↗

Molecular pathogenesis of Cutaneous T cell Lymphoma: Role of chemokines, cytokines, and dysregulated signaling pathwaysSemantic proximity Read ↗

Advances in the understanding and treatment of Cutaneous T-cell LymphomaSemantic proximity Read ↗

Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation.Semantic proximity Read ↗

Therapeutic Opportunities in Cutaneous T-cell LymphomaSemantic proximity Read ↗

Skin infiltrating NK cells in cutaneous T-cell lymphoma are increased in number and display phenotypic alterations partially driven by the tumorSemantic proximity Read ↗

Epigenetics in the Pathogenesis and Treatment of Cutaneous T-Cell LymphomaSemantic proximity Read ↗

Primary cutaneous T-cell lymphoma, unspecified, exhibiting an aggressive clinical course and a cytotoxic phenotype.Semantic proximity Read ↗

Cell signaling in cutaneous T‐cell lymphoma microenvironment: promising targets for molecular‐specific treatmentSemantic proximity Read ↗

[Epidermotropic T cell lymphomas as models for tumor progression].Semantic proximity Read ↗

Genetics of Cutaneous T Cell Lymphoma: From Bench to Bedside.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.